Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongmai Jiangtang Capsule is an orally administered, multi-herb traditional Chinese medicine product marketed in China for diabetes mellitus corresponding to the traditional syndrome of qi-yin deficiency with collateral stasis. The approved hard-capsule product contains taizishen, danshen, huanglian, huangqi, jiaogulan, shanyao, cangzhu, xuanshen, shuizhi, dongkuiguo, and gegen; the current product labeling identifies Baoding Tianhao Pharmaceutical as the marketing authorization holder and manufacturer and lists Chinese drug approval number Z20026853. A randomized, double-blind, placebo-controlled Phase 3 study is evaluating the capsule as an adjunct to standard care for prevention of major cardiovascular and cerebrovascular events in older patients with high-risk metabolic syndrome. ([buchang.com](https://www.buchang.com/FormMy/product/XiangXiChanPin?ID=8e3613d0-48df-4036-a303-9ed1c40dcfc7))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongmai Jiangtang Capsule.